Abstract P4-16-08: A regional audit of 6-hour monitoring for administration related reactions during the first administration of subcutaneous trastuzumab

Colin Murphy

doi:10.1158/1538-7445.sabcs18-p4-16-08

Abstract P4-16-08: A regional audit of 6-hour monitoring for administration related reactions during the first administration of subcutaneous trastuzumab

Colin Murphy

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Cancer Research
DOIs	https://doi.org/10.1158/1538-7445.sabcs18-p4-16-08
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Medicine
Tolerability
Trastuzumab
Breast cancer
Surgery
Anesthesia
Gynecology
Internal medicine
Cancer
Adverse effect

Access to Document

10.1158/1538-7445.sabcs18-p4-16-08

https://openalex.org/W2943905170Licence: CC BY-NC-ND

Cite this

@article{ff9f7fb3f6ad4458987b6a47e05ee56b,

title = "Abstract P4-16-08: A regional audit of 6-hour monitoring for administration related reactions during the first administration of subcutaneous trastuzumab",

keywords = "Medicine, Tolerability, Trastuzumab, Breast cancer, Surgery, Anesthesia, Gynecology, Internal medicine, Cancer, Adverse effect",

author = "Colin Murphy",

year = "2019",

doi = "10.1158/1538-7445.sabcs18-p4-16-08",

language = "English",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

}

TY - JOUR

T1 - Abstract P4-16-08: A regional audit of 6-hour monitoring for administration related reactions during the first administration of subcutaneous trastuzumab

AU - Murphy, Colin

PY - 2019

Y1 - 2019

KW - Medicine

KW - Tolerability

KW - Trastuzumab

KW - Breast cancer

KW - Surgery

KW - Anesthesia

KW - Gynecology

KW - Internal medicine

KW - Cancer

KW - Adverse effect

U2 - 10.1158/1538-7445.sabcs18-p4-16-08

DO - 10.1158/1538-7445.sabcs18-p4-16-08

M3 - Article

SN - 0008-5472

JO - Cancer Research

JF - Cancer Research

ER -